Granules India Limited has inaugurated two new Centres of Excellence at IIT Hyderabad’s Technology Research Park, strengthening its capabilities in advanced pharmaceutical research and development.

The first facility, the Ascelis Center of Excellence for Peptide Development and Characterization, will support work on cosmetic, therapeutic, and pharmaceutical peptides. It is equipped with in-house capabilities to analyze peptide structure at primary, secondary, and tertiary levels. This marks the first dedicated peptide development and characterization facility established under Granules’ CDMO arm, Ascelis Peptides.

The second facility, the Granules Center of Excellence for Particle Engineering, will focus on polymorph research, materials science, and novel drug-delivery systems such as amorphous solid dispersions. The centre replaces earlier external or ad-hoc development arrangements and is expected to enhance formulation efficiency and boost first-to-file opportunities in global regulatory markets.

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, said the launch of these Centres of Excellence underscores the company’s long-term commitment to scientific excellence and innovation. He noted that the facilities will accelerate advanced drug development, strengthen CDMO capabilities, and enhance global competitiveness.

With these new platforms, Granules aims to reduce dependency on outsourced R&D, expand its footprint in peptide therapeutics, and advance its position in high-quality formulation science.